Orna Therapeutics
Orna Therapeutics, founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, is a biotechnology company specializing in the development of fully engineered circular RNA therapeutics. The company's proprietary platform combines innovative technology to create circular RNAs that drive protein expression, coupled with validated delivery solutions. This approach aims to simplify production, enhance formula stability, and improve protein expression for treating various diseases.
ReNAgade Therapeutics
Acquisition in 2024
ReNAgade Therapeutics is dedicated to harnessing the potential of RNA therapeutics for disease treatment through innovative gene therapy technologies. The company has developed a proprietary platform that utilizes RNA delivery systems, enabling coding, editing, and gene insertion to create novel medications. Its advanced CRISPR-Cas9 system allows for precise gene editing, minimizing off-target effects and enhancing the durability of gene therapies. This technology aims to broaden the applications of gene therapy across various medical conditions, ultimately improving safety and effectiveness for patients. By focusing on an all-RNA system, ReNAgade Therapeutics seeks to revolutionize the landscape of RNA medicines and advance healthcare solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.